Glyscend
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
600 Suffolk St Ste 250, Lowell, Massachu...Phone Number
(617) 548-3513Website
www.glyscend.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Glyscend
Glyscend, Inc. is an innovative biotechnology company focused on developing oral polymer therapies that mimic the effects of bariatric surgery for the treatment of Type 2 Diabetes and obesity. Their unique approach offers the benefits of metabolic surgery without the associated risks, targeting overweight and obese patients through non-invasive means. With a team experienced in gastroenterology, metabolism, and drug development, Glyscend has contributed to numerous FDA-approved therapeutic products. The company is currently advancing its first-in-class oral drug candidate, GLY-200, in clinical trials.Explore more
Glyscend Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Glyscend your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Glyscend
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Glyscend launches new products
Earning: See what the market has to say on Glyscend recently announced quarterly report
Check if Glyscend has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Glyscend has new funding data
Click to see if Glyscend had a recent Job posting/layoffs
Check out if Glyscend is spiking on competitors!
Glyscend, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Glyscend
Compare insights from companies similar to Glyscend, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Glyscend is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Glyscend is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Glyscend.
Glyscend financials insights
Gather financial insights about Glyscend, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$20.5M
Glyscend Tech Stack
A closer look at the technologies used by Glyscend
Most Recent Scoops
Lateral Move
Executive Move
New Hire
Executive Move
New Hire
Executive Move
Glyscend has announced that Sapan Shah has joined the organization as Chief Executive Officer.
New Hire
Executive Move
Funding
Glyscend News & Media
Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
BOSTON--(BUSINESS WIRE)--Glyscend Therapeutics, a clinical-stage biopharmaceutical company that is reshaping the treatment of metabolic disease, including obesity and type 2 diabetes, with first-in-class oral polymer medicines that address unmet needs for patients globally, today announced the appointment of Sapan Shah, Ph.D., as Chief Executive Officer. Dr. Shah has more than 25 years of experience leading innovative life science companies as CEO, founder, board member and strategic advisor. HGlyscend Therapeutics Announces Publication of GLY-200 First-in-Human Data and Availability of Phase 2a Clinical Results
BOSTON--(BUSINESS WIRE)--Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies for the treatment of metabolic diseases including obesity and type 2 diabetes (T2D) today announced that safety and pharmacodynamic data from the first-in-human Phase 1 trial of GLY-200 were published in Diabetes, Obesity and Metabolism. The data published demonstrate that GLY-200, the company’s lead clinical candGlyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity
BOSTON--(BUSINESS WIRE)--Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered first-in-class gut-targeted polymer therapies, today announced clinical progress with its lead candidate, GLY-200, for the treatment of type 2 diabetes (T2D) and obesity. Data across completed Phase 1 and Phase 2a clinical trials demonstrated that the novel mechanism of GLY-200 offers significant and clinically relevant reductions in postprandial glucose andGlyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
BOSTON--(BUSINESS WIRE)--Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Michael Wyzga to its Board of Directors. Mr. Wyzga brings over two decades of deep experience leading and advising life sciences companies to the Glyscend Board. “We are thrilled to welcome Mike, a distinguished biotech industry expert, to the Glyscend team,” said Ashish Nimgaonkar, M.D., President and CEO
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Glyscend
Sign Up For FreeTo access detailed company insights
Glyscend, Inc. is an innovative biotechnology company focused on developing oral polymer therapies that mimic the effects of bariatric surgery for the treatment of Type 2 Diabetes and obesity. Their unique approach offers the benefits of metabolic surgery without the associated risks, targeting overweight and obese patients through non-invasive mea... Read More
